Radium-223 Dichloride Long-term Follow-up Program

This long-term follow up study will enroll subjects who will be transferred from selected
interventional, company sponsored trials with radium-223 dichloride (feeder trials).

The primary objectives are to define the long term safety profile of radium-223 dichloride
(for up to 7 years after the last dose of radium-223 dichloride); to assess the incidence of
leukemia, myelodysplastic syndrome, aplastic anemia, and primary bone cancer or any other new
primary malignancy; to assess the incidence of bone fractures and bone associated events
(e.g., osteoporosis); and, in subjects who receive cytotoxic chemotherapy, to assess the
incidence of febrile neutropenia and hemorrhage during their chemotherapy treatment and for
up to 6 months thereafter at a frequency based on local clinical practice.

Inclusion Criteria:

- Subject was previously enrolled in a selected company sponsored feeder trial, and has
received at least 1 dose of radium 223 dichloride or placebo in the feeder trial

Exclusion Criteria:

- Not applicable to this follow up study